17.11
-2.73%
Close of 20 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
Price performance
Chart by TradingView, with its own licensed prices
- Market value
- $2.84bn
- Last close × shares
- Volume
- 1.9m
- Shares, 20 Nov 2026
- Price to earnings
- 15.8
About ACADIA Pharmaceuticals
From its filings with the US Securities and Exchange Commission
ACADIA Pharmaceuticals is based in San Diego, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ACAD. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $1.07bn and net income of $391.0m. At that date it held total assets of $1.56bn and shareholders' equity of $1.23bn. By business, NUPLAZID brought in 63.5% of revenue, followed by DAYBUE at 36.5%.
We are a biopharmaceutical company focused on turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world.
We have two core franchises in neurological and rare diseases. Our neurological disease franchise is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). Our rare disease franchise is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Net product sales from these two commercial products totaled $1,071.5 million for 2025, compared with $957.8 million for 2024.
In addition to these commercial products, we have a portfolio of product candidates and research programs that are designed to address significant unmet medical needs in neurological and rare diseases. In order to achieve significant long-term growth, we plan to develop our current portfolio, expand our pipeline of early- and late-stage product candidates and expand into areas of rare disease that are adjacent to our existing franchises, including through strategic business development, and make use of our internal capabilities and knowledge.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Latest on ACADIA Pharmaceuticals
Our reporting
- ACADIA Pharmaceuticals falls 2.73% in Friday's session
- ACADIA Pharmaceuticals falls 2.67% in Wednesday's session
- ACADIA Pharmaceuticals rises 3.36% in Friday's session
- ACADIA Pharmaceuticals rises 10.79% in Tuesday's session
- ACADIA Pharmaceuticals falls 22.28% in Monday's session
- ACADIA Pharmaceuticals rises 4.38% in Wednesday's session
Next results
Due on 24 Feb 2027. Analysts expect earnings of 0.28 a share.
Other Health Care listings
Scenario calculator
Try your own numbers. This is arithmetic, not a forecast.
Gain or loss
Return
Leaves out fees, taxes and financing.
Frequently asked questions
What is ACADIA Pharmaceuticals's ticker?
ACADIA Pharmaceuticals trades as ACAD on its US listing, under ISIN US0042251084.
What was ACADIA Pharmaceuticals's last closing price?
17.11 on 20 Nov 2026. The figure is in USD and is never converted.
When does ACADIA Pharmaceuticals next report results?
Results are expected on 1 Mar 2027, according to our data supplier.
Sources and methodology
- Chart
- TradingView
- Close and company data
- SEC filings and our data supplier
- News
- Our reporting
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.